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unlicensed comparator bevacizumab, the frequency and duration of treatment, and 
the extrapolation of visual acuity beyond short-term observed trial data. The trial 
evidence used ranged from 6 months to 3 years and included evidence for treatment 
in one eye only. Most TAs modelled one treated eye only, with crude adjustments 
applied to account for bilateral treatment. Only the most recent appraisal for afliber-
cept in central RVO modelled the visual acuity of both eyes. All other uncertainties 
were consistent throughout the identified TAs. ConClusions: The main uncer-
tainties are in which eye(s) patients are treated in practice and the extrapolation of 
outcomes beyond trial data. Modelling is limited by short-term clinical trial evidence 
that provides evidence for the treatment of one eye only.
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objeCtives: Standard approaches to evaluating the health economic benefit of avoid-
ing hypoglycaemia often attribute a per-event disutility (PED) with growing evidence 
of the diminishing marginal effects (DME) of hypoglycaemia on utility as frequency 
increases. This study compared PED to DME on predicted quality adjusted life expec-
tancy (QALE). Methods: This study used the CORE Diabetes Model (CDM) and pub-
lished audit data for patients with type 1 diabetes switching to insulin degludec (ID) 
from either insulin glargine or detemir (IGD). Mean (± SD) baseline profiles were age 
35.0 years (± 11.4); diabetes duration 18.2 years (± 7.5); HbA1c 9.4% (±0.8); weight 77.0 
kg (±10.7) and 3.9 hypoglycaemia (severe and non-severe) events per week (±0.9). 
Mean change in clinical variables was HbA1c -0.5% (±0.3); weight +0.8g (±1.6) and 
hypoglycaemia events/week -3.6 (±0.9). A baseline cohort was projected over a lifetime 
using the CDM using published PED disutility (-0.0052) and published DME disutility 
(0.0141*[number of events]^0.3393) with and without treatment effects applied to cal-
culate life expectancy (LE) and QALE associated with the pre and post-switch profiles. 
Results were discounted at 3.5%. Results: Overall discounted LE was 18.8 years and 
19.06 years for IGD and ID profiles respectively and discounted QALE (ignoring the 
impact of hypoglycaemia) was 12.13 and 12.4 for IGD and ID respectively. Discounted 
QALE was reduced by 1.85 (IGD) and 0.849 (ID) using the DME approach applied to 
hypoglycaemia rates of 3.9 and 0.4 events/week respectively. Using the PED approach 
discounted QALE was reduced by 22.96 (IGD) and 2.355 (ID). The PED approach resulted 
in a QALE prediction less than zero for IGD. ConClusions: Failure to adequately 
accommodate the relationship between hypoglycaemia frequency and utility within 
health economic evaluations may lead to misleading predictions and estimates of 
QALE that lack face validity; particularly when hypoglycaemia rates are high.
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objeCtives: End-stage renal disease (ESRD) poses a significant burden to both 
patients and healthcare systems. In patients with type 2 diabetes mellitus (T2DM) 
improvements in the management of cardiovascular (CV) risk factor management 
has reduced CV specific morbidity and mortality. Consequently, as patients live 
longer with T2DM it is likely that the incidence and prevalence of renal disease will 
increase over time. The objective of this study was to externally validate the renal 
specific disease progression rates used in the IMS CORE diabetes model (CDM) to 
the UKPDS 64 and UK clinical practice. Methods: A Markov state transition model 
was developed to predict the progression of renal disease populated with transition 
probabilities from the CDM (derived from US and Israeli published studies) and the 
UKPDS 64 nephropathy model. Time to ESRD and the cumulative percentage with 
ESRD at 10, 20 and 40 years, or lifetime, whichever occurred first, were compared and 
contrasted with published ESRD projections derived from UK clinical practice data 
(The Health Improvement Network [THIN]). Baseline patient characteristics were 
taken from published THIN data. Results: For T2DM subjects aged 51 with mean 
systolic blood pressure of 139mmHg and HbA1c of 8% the predicted time to ESRD 
was 23.39 and 24.02 years when using CDM and UKPDS 64 transition rates, respec-
tively. The cumulative incidence of ESRD at 10, 20 and 40 years was 2.21%, 10.04% and 
24.96% respectively with CDM and 3.29%, 9.88% and 26.73% with UKPDS 64. Predicted 
20-year cumulative risk of ESRD from THIN varied between 5-18% dependent upon 
cohort characteristics, consistent with output from both CDM (10.04%) and UKPDS 
(9.88%). ConClusions: This study provides evidence of the consistency between 
approaches to modelling renal disease employed by the CDM and reported from 
UKPDS; furthermore, both approaches provide estimates consistent with data from 
UK clinical practice.
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objeCtives: Remission, the spontaneous resolution of symptoms among patients, 
is one of the characteristics of chronic spontaneous (or idiopathic) urticaria (CSU/
CIU). Limited literature currently exists regarding remission rates among chronic urti-
caria (CU) or CSU/CIU patients and available estimates vary. Due to the requirements 
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objeCtives: To compare cost-effectiveness of delayed-release dimethyl-fuma-
rate (DMF; also known as gastro-resistant DMF) vs. pharmacological alternatives 
indicated for the first-line treatment of relapsing-remitting multiple sclero-
sis (RRMS), adopting the perspective of the Italian National Healthcare Service 
(NHS). Methods: A cost-effectiveness model was used to evaluate costs and 
outcomes of patients treated with DMF, vs. interferon beta-1a intramuscular (IFN 
beta-1a, IM), interferon beta-1a subcutaneous, at two different doses (IFN beta-1a, 
SC 22mcg and SC 44mcg), interferon beta-1b subcutaneous (IFN beta-1b, SC), glati-
ramer acetate subcutaneous (GA), and oral teriflunomide (TER). The Markov model 
used for the analysis evaluated the effects of disability progression, relapses, and 
treatment-related adverse events, on direct healthcare costs and quality adjusted 
survival of RRMS patients, over a 50-year (lifetime) horizon. Comparative effec-
tiveness and safety data used in the model were derived from a mixed treatment 
comparison. All unit tariffs and costs were adapted to the Italian setting. Results: 
Lifetime direct healthcare costs associated with DMF were € 276,500 per patient, 
yielding to 19.50 life-years (LYs) and 6.55 quality-adjusted LYs (QALYs). The incre-
mental cost-effectiveness ratio (ICER) of DMF vs. the analyzed alternatives ranged 
between € 11,272 per QALY gained (DMF vs. IFN-beta 1b SC) to € 23,409 per QALY 
gained (DMF vs. TER). DMF was dominant vs. IFN-beta 1a SC 44mcg. Probabilistic 
sensitivity analysis conducted on both clinical and economic data showed that like-
lihood for DMF of being cost-effective, using a willingness-to-pay (WTP) threshold of 
€ 50,000 per QALY gained, was between 70.0% (DMF vs. TER), and 92.8% (DMF vs. IFN-
beta 1b, SC). ConClusions: At the current pricing and reimbursement conditions 
established by the Italian NHS, DMF represents a cost-effective option vs. first-line 
treatments indicated in RRMS. ICER associated with DMF is much lower than the 
€ 50,000 per QALY gained value, the cost-effectiveness of dialysis, commonly used 
in Italy as benchmark to issue positive funding recommendation.
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objeCtives: We demonstrate an approach to assess the impact of uncertainty in 
risk predictions on health-economic outcomes in risk-stratified prevention strate-
gies, illustrated for preventive statin treatment based on 10-year coronary heart 
disease (CHD) risk predicted by the Framingham risk score (FRS). Methods: We 
refitted the FRS to three random samples of increasing size (N= 2,500, N= 1,000, 
N= 500) from a population-based cohort. A Markov decision-analytic model was 
used to simulate cohorts with preventive statin treatment in high-risk (FRS≥ 20%) 
individuals (ATPIII guideline). This treatment threshold was incrementally lowered 
to T= 0.0% with 0.5% decrements. Using the cohort the distribution of individuals 
over the low (< 0.5T%), intermediate (0.5T%-T%), and high (≥ T%) risk category and 
corresponding observed CHD-risks were calculated. The Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) was calculated and uncertainty in outcomes 
was assessed with probabilistic sensitivity analysis. The NHB for each 0.5% risk 
category was calculated to assess the impact of risk prediction uncertainty on asso-
ciated uncertainty in NHB. Results: Prediction model performance was fair in all 
samples (c-statistic: 0.70-0.75). Prediction uncertainty resulted in probabilities of 
incorrect treatment decisions of up to 0.4 (N= 2,500) and 0.5 (N= 500) for risk around 
T= 20.0%. The NHBs per risk category ranged from -0.031 for a predicted risk of 
[3.5%;4%] to 0.020 for [10.0%;10.5%] in men and from -0.067 at [0.0%;0.5%] to 0.045 
for [2.0%;2.5%] in women. The NHB was positive for predicted risks > 12.5% in men 
and > 11.5% in women. For individuals with predicted risks < 7.5% or > 20%, in 95% 
of PSA simulations the NHB was negative or positive, respectively. ConClusions: 
Risk-stratified prevention is increasingly recommended. While uncertainty in risk 
predictions may lead to incorrect treatment decisions, associated impact on long-
term health-economic outcomes is unknown. Assessing this impact can guide 
studies aiming to improve prediction models by focusing on individuals for which 
improvement may actually improve health-economic outcomes.
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objeCtives: To identify and summarise challenges to the economic model-
ling of macular oedema due to retinal vein occlusion (RVO) and diabetic macu-
lar oedema (DMO). Methods: National Institute for Health and Care Excellence 
(NICE) technology appraisals (TAs) for RVO and DMO published before 1 June 2015 
were reviewed to identify areas of uncertainty in submitted economic models. 
Evaluations were compared to assess whether, over time, these uncertainties have 
been addressed. Results: Three completed NICE TAs were identified for RVO and 
two for DMO. The main area of uncertainty identified related to whether patients 
would be treated in their better-seeing eye (BSE), worse-seeing eye (WSE) or both 
eyes (bilateral), and consequently how this should be modelled. This had implica-
tions for the appropriate application of utility estimates for patients treated in the 
BSE, WSE or bilaterally and for the classification of patients as blind. Blindness is 
associated with high costs and low quality of life, which were incorrectly accounted 
for in one-eye models. Other areas of uncertainty included the relevance of the 
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objeCtives: Although the fracture risk assessment tool (FRAX) developed by WHO 
is considered to be valid and reliable, its algorithm is not open to the public and is 
thus unavailable for economic evaluations. The purpose of this study was to develop 
a state transition model with risk equations for osteoporotic fracture in Japanese 
women and to verify the validity of our model by comparison of the predicted 
10-year osteoporotic fracture probabilities in our model and those derived from 
the FRAX. Methods: Equations for age and femoral neck BMD specific incidence 
of hip, clinical spine, and other fracture were developed using a series of methods 
by De Laet, et al and epidemiological data of postmenopausal Japanese women. A 
patient-level state transition model with ten health states using the equations was 
used to predict the 10-year probability of a hip fracture and a major osteoporotic 
fracture in Japanese women with osteoporosis, who had no treatments. We ran 
the model with different combinations of BMD (T-score−1.5, −2.0, or −2.5), and the 
number of clinical risk factors (0, 1, 2, or 3). The predicted values in our model were 
compared with those of the FRAX. Results: For 70-year-old women with differ-
ent combinations of T-scores and the number of clinical risk factors, the estimated 
10-year probabilities of hip fracture in our model were almost identical to those 
of the FRAX. The 10-year probabilities of major osteoporotic fracture in our model 
also appeared to be consistent with those of the FRAX. These findings supported 
the validity of our model in the use of health economic evaluation. ConClusions: 
The developed model appears to be a valid model for use in economic evaluation in 
osteoporosis from the perspective of Japan healthcare system. The relation between 
10-year fracture probability and ICER of osteoporosis treatment can be estimated 
using this model.
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objeCtives: To develop and validate a conceptual model (CM) of multiple myeloma 
(MM) for use in economic modelling that characterises the disease in terms of 
attributes that impact on disease progression and outcomes. Methods: A draft 
CM was developed using two systematic literature reviews to identify attributes of 
MM that appeared to impact on disease progression and outcomes. These attributes 
were grouped according to the aspects they measured (e.g. symptoms) and then 
linked to denote relationships across groups. This was discussed and validated 
by a Delphi panel of four MM experts. For simplicity, the CM did not consider the 
impact of treatment Results: Consensus was reached about the attributes to be 
included in the CM: baseline and disease characteristics (age, comorbidities, Eastern 
Cooperative Oncology Group performance status and genetic factors), central 
associations (disease activity, complications and symptoms) and final outcomes 
(overall survival [OS], quality of life). Disease activity was measured by several fac-
tors, including M-protein and serum lactate dehydrogenase. There was consensus 
that most genetic factors [e.g. t(4;14), del(13p)] influenced disease activity, which 
in turn affected complications (e.g. anaemia, renal complications). Symptoms (e.g. 
pain, bone fractures) were influenced by genetic factors and disease activity. Disease 
activity, comorbidities and complications impacted on OS. Consensus was not 
reached for the impact of age/comorbidities on complications/symptoms, nor for 
the influence of del(17p) on complications. ConClusions: There was agreement on 
the attributes that should be used to characterise and understand MM; however, the 
lack of consensus on the association between some attributes reflects the relatively 
limited understanding of how aspects of MM impact on disease progression and 
outcomes. Future studies should focus on understanding the gaps identified. This 
CM may be used in economic modelling and could form the foundation for devel-
oping disease-based MM models to explore the impact of treatment on outcomes.
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objeCtives: With a variety of medical technologies under development to 
address the increasing prevalence of Alzheimer’s Disease (AD) and Mild Cognitive 
Impairment (MCI), stakeholders need methods to assess and compare their value. 
The Clinical Dementia Rating (CDR) Sum of Boxes (SOB) scale can be used to stage 
AD and MCI severity, but has not previously been incorporated into cost-effective-
ness analysis (CEA) models. We developed a CEA framework to evaluate effective-
ness using the increasingly common CDR-SOB endpoint. Methods: A systematic 
literature review was conducted to identify published AD and MCI cost-effective-
ness models. The review identified no models that evaluated effectiveness using 
the CDR-SOB score. To facilitate use of this measure in future health economic 
evaluations, we developed a state-transition model that synthesizes prior study 
results to link CDR-SOB score changes to MMSE health states. We then applied 
standard health state utilities and direct medical expenditure values from prior 
AD and MCI CEAs. Results: We mapped CDR-SOB scores to MMSE health states 
using the results from Delor et al. (2013) and O’Bryant et al. (2008), and extrapolated 
long-term (5+ year) disease progression using a variety of curve fits. Based on the 
baseline CDR-SOB score distribution, patients were assigned to one of five health 
of economic modelling (e.g. cycle length), these estimates cannot be incorporated 
directly. The objective was to adapt the remission rates to model cycle length, using 
various statistical methods. Methods: From a systematic review, 4 studies reporting 
proportions of patients undergoing remission at different time points were identified. 
One of the studies reported data for 2 populations (CSU/CIU and all chronic urticaria 
patients), therefore, 5 populations were considered in total. A four-step approach 
was undertaken: (1) converting reported data to standard time units; (2) using the 
extracted data to run the Kaplan-Meier (K-M) analysis; (3) applying four statistical 
distributions (exponential, log-normal, weibull and log-logistic) to identify the distri-
bution best fitting the literature estimates. Lowest Kolmogorov-Smirnov (KS) distance 
was chosen as the criterion for the best fit distribution; (4) values obtained from the 
best fit distribution were further converted into rates for each 4-week cycle length. 
The analysis was carried out for 78 years to correspond to the lifetime horizon of the 
cost-effectiveness model. Results: Based on the KS distance, log-normal distribu-
tion was the best fit for 2 populations and log-logistic for 3 populations. Remission 
rates were generated for these 5 populations which ranged from 9.5% to 37.7% for 
year 1, 29.5% to 70.8% for year 5 and 49.6% to 91.5% for year 20. ConClusions: This 
approach provides a robust statistical method for adapting the literature estimates 
as per the requirements of an economic model. Due to the wide range of remission 
estimates in the literature, face validation via expert clinical opinion is recommended 
to determine appropriate model inputs.
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objeCtives: Functional dyspepsia or gastrointestinal disorders are extremely com-
mon in Germany. Estimates suggest that a total of 15-30% of adults suffer from func-
tional disorders. The aim of this study was to identify and weight the decision expert’s 
relevant decision criteria with regard to the drug treatment of functional dyspepsia 
or motility disorders. Attributes such as onset of action, reduction of symptoms and 
side effects were to be examined in order to test their relevance to health care deci-
sion makers. Methods: On the basis of a literature search and qualitative patient 
(N= 6) and expert interviews (N= 4), a questionnaire was developed. By means of the 
analytic hierarchy process (AHP), the study elicited the priorities regarding various 
aspects of treatments of dyspepsia and motility disorders. The collection of data 
from experts of the field of gastroenterology was done in real time within the con-
text of a group discussion using an item-response-system. Results: As a result of 
the interviews, seven characteristics were established which were judged to be the 
most important. A total of N= 20 experts took part in the group discussion and the 
AHP survey. For all participants the criterion “reduction of abdominal cramps” was 
the most important attribute of a drug treatment. It became clear that reduction of 
symptoms, time to onset of action and risk of side-effects were of central importance. 
Consequently, the following criteria were assessed to be most relevant: reduction of 
abdominal cramps (w:0.302), reduction of epigastric pain (w:0.250) and time to onset 
of action (w:0.117). ConClusions: The AHP represents a suitable and scientifically 
transparent approach for the elicitation of experts’ priorities within the context of 
group discussions. The item response system served as a valuable instrument to 
collect quantitative data based on a group discussion. The patient perspective in a 
subsequent discrete-choice experiment will expand the findings of this study.
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objeCtives: Demonstrating face validity in health economic models enhances 
their credibility and is important if the model’s output is to robustly inform health-
care decision-making. Type 2 diabetes (T2DM) models are typically complex and 
their results are influenced by multiple factors including treatment effects, cohort 
characteristics, choice of rescue therapies and structural settings, such as ther-
apy escalation thresholds. The objective of this study was to illustrate the impact 
that baseline HbA1c and HbA1c trajectories exerts on time to therapy escalation 
when using guideline therapy escalation thresholds compared with clinical prac-
tice. Methods: Using the UKPDS 68 HbA1c trajectory equation implemented within 
the IMS CORE diabetes model, the time to therapy escalation was assessed as a 
function of baseline HbA1c (7.0%, 7.5%, 8.0% and 8.5%) with therapy escalation 
thresholds recommended by NICE (7.5%) versus those observed in clinical practice 
in the UK (8.5%). Published data informed initial HbA1c treatment effects of -0.93% 
(standard deviation 0.17%). Second order uncertainty was utilised with baselines 
HbA1c, treatment reduction and HbA1c trajectories sampled; results were averaged 
over 10,000 simulations. Results: Using NICE escalation criteria (7.5%) mean (SD) 
time to escalation was 6.6 (0.6), 5.2 (0.5), 3.6 (0.5) and 1 (0.0) years for cohorts with 
baseline HbA1c of 7.0%, 7.5%, 8.0% and 8.5% respectively. Using escalation levels 
observed in clinical practice (8.5%) mean (SD) time to escalation was 17.4 (4.3), 14.0 
(3.2), 11.2 (2.4) and 8.9 (1.9) years for cohorts with baseline HbA1c of 7.0%, 7.5%, 
8.0% and 8.5% respectively. ConClusions: The use of aspirational guideline based 
therapy escalation thresholds has the potential to significantly impact the expected 
time to therapy escalation and the variability in timing. As duration on therapy is 
a key driver in cost effectiveness studies, parameters controlling timing of therapy 
escalation should be robustly explored in sensitivity analysis.
PRM89
ValIdaTIon of fRacTuRe RIsK Model In jaPanese WoMen coMPaRed 
WITh fRax
Moriwaki K1, Noto S2
